ARLINGTON, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the third quarter and nine months ended September 30, 2024.
Third Quarter Performance
| For the Three Months Ended September 30, | |||||||||
| ($ in millions, except per share amounts) | 2024 | 2023 | Change (%) | ||||||
| Total revenue | $ | 437.9 | $ | 417.3 | 4.9 | % | |||
| Gross profit | $ | 99.9 | $ | 90.6 | 10.2 | % | |||
| Operating income | $ | 5.8 | $ | 5.5 | 5.0 | % | |||
| Net income a | $ | 3.5 | $ | 5.6 | (37.4)% | ||||
| Non-GAAP adjusted net income b | $ | 25.1 | $ | 21.1 | 19.0 | % | |||
| Net income per share | $ | 0.03 | $ | 0.05 | (40.0)% | ||||
| Non-GAAP adjusted net income per share | $ | 0.20 | $ | 0.17 | 17.6 | % | |||
| |||||||||
Key Operating and Non-GAAP Financial Metrics
| For the Three Months Ended September 30, | |||||||||
| ($ in millions) | 2024 | 2023 | Change (%) | ||||||
| Implemented Providers | 4,642 | 4,105 | 13.1 | % | |||||
| Value-Based Care Attributed Lives | 1,247,000 | 1,094,000 | 14.0 | % | |||||
| Practice Collections | $ | 739.9 | $ | 723.5 | 2.3 | % | |||
| Care Margin | $ | 101.4 | $ | 92.1 | 10.2 | % | |||
| Platform Contribution | $ | 50.3 | $ | 45.2 | 11.2 | % | |||
| Adjusted EBITDA | $ | 23.6 | $ | 18.8 | 25.8 | % | |||
Third Quarter 2024 business highlights include:
Nine-Month Performance
| For the Nine Months Ended September 30, | |||||||||
| ($ in millions, except per share amounts) | 2024 | 2023 | Change (%) | ||||||
| Total revenue | $ | 1,275.5 | $ | 1,216.9 | 4.8 | % | |||
| Gross profit | $ | 291.6 | $ | 263.8 | 10.5 | % | |||
| Operating income | $ | 11.7 | $ | 19.2 | (39.0)% | ||||
| Net income a | $ | 10.0 | $ | 20.2 | (50.7)% | ||||
| Non-GAAP adjusted net income b | $ | 71.1 | $ | 61.1 | 16.3 | % | |||
| Net income per share | $ | 0.08 | $ | 0.16 | (50.0)% | ||||
| Non-GAAP adjusted net income per share | $ | 0.57 | $ | 0.49 | 16.3 | % | |||
| |||||||||
Key Operating and Non-GAAP Financial Metrics
| For the Nine Months Ended September 30, | |||||||||
| ($ in millions) | 2024 | 2023 | Change (%) | ||||||
| Implemented Providers | 4,642 | 4,105 | 13.1 | % | |||||
| Value-Based Care Attributed Lives | 1,247,000 | 1,094,000 | 14.0 | % | |||||
| Practice Collections | $ | 2,175.6 | $ | 2,082.4 | 4.5 | % | |||
| Care Margin | $ | 296.1 | $ | 267.7 | 10.6 | % | |||
| Platform Contribution | $ | 142.4 | $ | 131.2 | 8.5 | % | |||
| Adjusted EBITDA | $ | 65.6 | $ | 55.0 | 19.3 | % | |||
New Market Entry
Privia Health today announced it has entered the state of Indiana in partnership with a multi-specialty practice with more than 35 providers, which will serve as the anchor practice for Privia Medical Group Indiana.
MSSP 2023 Performance
Privia’s Accountable Care Organizations (ACO) again delivered solid 2023 performance results for the Medicare Shared Savings Program (MSSP). The results were publicly released in late October 2024 by the Centers of Medicare and Medicaid Services (CMS) The 10 Privia ACOs achieved aggregate shared savings of $176.6 million, a 34.1% increase from 2022.
Capital Resources
The Company's balance sheet at September 30, 2024, included cash and cash equivalents of $422.0 million no debt, and an undrawn $125 million Revolving Credit Facility. The Company’s cash balance does not include approximately $51.5 million in cash (after expenses and provider disbursements) expected to be received by year-end 2024 from the CMS as payment for Privia Health’s portion of the shared savings generated in the 2023 performance year of the MSSP. Pro forma for the expected cash receipt from CMS, the Company’s cash balance would be $473.5 million.
Financial and Business Outlook c d e f
Privia Health raised its full-year 2024 guidance, as follows:
| FY 2023 | Initial FY 2024 Guidance at 2.27.24 c | Current FY 2024 Guidance at 11.7.24 | ||||||||
| ($ in millions) | Actual | Low | High | |||||||
| Implemented Providers | 4,305 | 4,650 | 4,750 | High End | ||||||
| Attributed Lives | 1,120,000 | 1,150,000 | 1,200,000 | Above High End | ||||||
| Practice Collections | $ | 2,839.0 | $ | 2,775 | $ | 2,875 | High End | |||
| GAAP Revenue | $ | 1,657.7 | $ | 1,600 | $ | 1,675 | High End | |||
| Care Margin | $ | 359.2 | $ | 388 | $ | 400 | High End | |||
| Platform Contribution | $ | 173.5 | $ | 180 | $ | 188 | High End | |||
| Adjusted EBITDAe | $ | 72.2 | $ | 85 | $ | 90 | High End | |||
| c. | Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of gross margin, operating income and net income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures. |
| d. | See “Key Metrics and Non-GAAP Financial Measures” for more information as to how the Company defines and calculates Implemented Providers, Attributed Lives, Practice Collections, Care Margin, Platform Contribution, and Adjusted EBITDA, and for a reconciliation of the most comparable GAAP measures to Care Margin, Platform Contribution, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income Per Share. |
| e. | Certain non-recurring or non-cash and other expenses will be treated as an add back in the reconciliation of Net Income to Adjusted EBITDA, and the reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share, the details of which can be found in the Reconciliation schedules near the end of this and in future quarterly financial press releases. |
| f. | Any slight variations in totals due to rounding. |
Webcast and Conference Call Information
The Company will host a conference call on November 7, 2024, at 8:00 am ET to discuss these results and management’s outlook for future financial and operational performance. You can visit ir.priviahealth.com/news-and-events/events-and-presentations to listen to the call via live webcast. The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call under the same link. If you wish to participate in the live conference call, then dial 888-596-4144 (or 646-968-2525 for international callers) and provide Conference ID 5704885.
This news release and the financial statements contained herein, and the slide presentation for the webcast, are also available on the Privia Health Investor Relations website at ir.priviahealth.com.
About Privia Health
Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. Our platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.
Non-GAAP Financial Measures
The Company reports and discusses its operating results using financial measures consistent with accounting principles generally accepted in the United States ("GAAP"). From time to time, in press releases, financial presentations, earnings conference calls or otherwise, the Company may disclose certain non-GAAP financial measures. The non-GAAP financial measures presented in this press release should not be viewed as alternatives or substitutes for the Company's reported GAAP results. A reconciliation to the most directly comparable GAAP financial measure is set forth in the tables that accompany this release.
The Company believes that the non-GAAP financial measures presented in this press release are relevant and provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because the measures allow them to understand and compare the Company's actual and expected operating results during the prior, current and future periods in a more consistent manner. The non-GAAP measures presented in this press release may not be comparable to similarly titled measures used by other companies. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provides a more complete understanding of the results of operations and trends affecting the Company's business. These non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to financial measures calculated in accordance with GAAP.
Safe Harbor Statement
The financial results in this press release reflect preliminary, unaudited results, which are not final until the Company’s Form 10-Q is filed with the Securities and Exchange Commission (“SEC”). This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as “aims,” “anticipates,” "assumes," “believes,” “estimates,” “expects,” “forecasts,” “future,” “intends,” “likely,” “may,” “outlook,” “plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,” “trends,” “will,” “would,” “could,” “should,” and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to, among other things: our future actions, business plans, objectives and prospects; and our future operating or financial performance and projections, including our full-year guidance for 2024. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements.
Factors related to these risks and uncertainties include, but are not limited to: any failure by the Company to comply with applicable healthcare laws and government regulations in the heavily regulated industry in which the Company operates; the impact of changes in applicable laws, rules or regulations, including with respect to health plans and payers and our relationships with such plans and payers, and provisions that impact Medicare and Medicaid programs; the Company’s dependence on relationships with its medical groups, some of which the Company does not own; the Company’s growth strategy, which may not prove viable and the Company may not realize expected results; difficulties implementing the Company’s proprietary end-to-end, cloud-based technology solution for Privia physicians and new medical groups; the high level of competition in the Company’s industry and any failure by the Company to compete effectively and innovate; challenges in successfully establishing a presence in new geographic markets; the Company’s reliance on its electronic medical record vendor, which the Privia Technology Solution is integrated and built upon; changes in the payer mix of patients and potential decreases in the Company’s reimbursement rates as a result of consolidation among commercial payers; the financial and operational impact of complying with various complex and changing federal and state privacy and security laws and regulations related to Company’s use, disclosure, and other processing of personal information and protected health information, including the Health Insurance Portability and Accountability Act of 1996; the impact of actual and potential cybersecurity incidents or privacy and security breaches involving us, our vendors or other third parties; the continued availability of a qualified workforce, including staff at our medical groups, and the continued upward pressure on compensation for such workforce; and those factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the Company’s subsequent Quarterly Reports on Form 10-Q. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
| Contact: |
| Robert Borchert |
| SVP, Investor & Corporate Communications |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |
| 817.783.4841 |
Privia Health Group, Inc.
Condensed Consolidated Statements of Operations(g)
(unaudited)
(in thousands, except share and per share data)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Revenue | $ | 437,921 | $ | 417,282 | $ | 1,275,490 | $ | 1,216,909 | ||||
| Operating expenses: | ||||||||||||
| Provider expense | 336,501 | 325,222 | 979,373 | 949,195 | ||||||||
| Cost of platform | 56,068 | 50,324 | 167,231 | 145,254 | ||||||||
| Sales and marketing | 7,047 | 7,241 | 19,984 | 18,483 | ||||||||
| General and administrative | 30,695 | 27,228 | 91,732 | 79,987 | ||||||||
| Depreciation and amortization | 1,797 | 1,731 | 5,436 | 4,761 | ||||||||
| Total operating expenses | 432,108 | 411,746 | 1,263,756 | 1,197,680 | ||||||||
| Operating income | 5,813 | 5,536 | 11,734 | 19,229 | ||||||||
| Interest income, net | 2,164 | 2,894 | 8,114 | 5,524 | ||||||||
| Income before provision for income taxes | 7,977 | 8,430 | 19,848 | 24,753 | ||||||||
| Provision for income taxes | 3,999 | 2,488 | 8,171 | 6,049 | ||||||||
| Net income | 3,978 | 5,942 | 11,677 | 18,704 | ||||||||
| Less: Net income (loss) attributable to non-controlling interests | 443 | 299 | 1,691 | (1,537 | ) | |||||||
| Net income attributable to Privia Health Group, Inc. | $ | 3,535 | $ | 5,643 | $ | 9,986 | $ | 20,241 | ||||
| Net income per share attributable to Privia Health Group, Inc. stockholders – basic | $ | 0.03 | $ | 0.05 | $ | 0.08 | $ | 0.17 | ||||
| Net income per share attributable to Privia Health Group, Inc. stockholders – diluted | $ | 0.03 | $ | 0.05 | $ | 0.08 | $ | 0.16 | ||||
| Weighted average common shares outstanding – basic | 119,658,574 | 117,602,059 | 119,156,368 | 116,266,938 | ||||||||
| Weighted average common shares outstanding – diluted | 125,751,006 | 124,924,442 | 125,457,540 | 124,646,849 | ||||||||
(g) Any slight variations in totals due to rounding.
Privia Health Group, Inc.
Condensed Consolidated Balance Sheets(h)
(in thousands)
| September 30, 2024 | December 31, 2023 | ||||||
| Assets | (unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 421,997 | $ | 389,511 | |||
| Accounts receivable | 408,959 | 290,768 | |||||
| Prepaid expenses and other current assets | 22,797 | 20,525 | |||||
| Total current assets | 853,753 | 700,804 | |||||
| Non-current assets: | |||||||
| Property and equipment, net | 1,456 | 2,325 | |||||
| Operating right-of-use asset | 5,288 | 6,612 | |||||
| Intangible assets, net | 103,070 | 107,630 | |||||
| Goodwill | 139,457 | 138,749 | |||||
| Deferred tax asset | 27,569 | 35,200 | |||||
| Other non-current assets | 14,972 | 8,580 | |||||
| Total non-current assets | 291,812 | 299,096 | |||||
| Total assets | $ | 1,145,565 | $ | 999,900 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued expenses | $ | 65,641 | $ | 57,831 | |||
| Provider liability | 411,252 | 326,078 | |||||
| Operating lease liabilities, current | 2,580 | 3,043 | |||||
| Total current liabilities | 479,473 | 386,952 | |||||
| Non-current liabilities: | |||||||
| Operating lease liabilities, non-current | 3,597 | 5,246 | |||||
| Other non-current liabilities | 313 | 313 | |||||
| Total non-current liabilities | 3,910 | 5,559 | |||||
| Total liabilities | 483,383 | 392,511 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Common stock | 1,199 | 1,182 | |||||
| Additional paid-in capital | 797,315 | 753,869 | |||||
| Accumulated deficit | (183,628 | ) | (193,614 | ) | |||
| Total Privia Health Group, Inc. stockholders’ equity | 614,886 | 561,437 | |||||
| Non-controlling interest | 47,296 | 45,952 | |||||
| Total stockholders’ equity | 662,182 | 607,389 | |||||
| Total liabilities and stockholders’ equity | $ | 1,145,565 | $ | 999,900 | |||
(h) Any slight variations in totals are due to rounding.
Privia Health Group, Inc.
Condensed Consolidated Statements of Cash Flows(i)
(unaudited)
(in thousands)
| For the Nine Months Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Cash flows from operating activities | |||||||
| Net income | $ | 11,677 | $ | 18,704 | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Depreciation | 876 | 878 | |||||
| Amortization of intangibles | 4,560 | 3,883 | |||||
| Stock-based compensation | 41,401 | 25,429 | |||||
| Deferred tax expense | 7,631 | 5,179 | |||||
| Changes in asset and liabilities: | |||||||
| Accounts receivable | (118,191 | ) | (156,219 | ) | |||
| Prepaid expenses and other current assets | (4,272 | ) | (2,801 | ) | |||
| Other non-current assets and right-of-use asset | (70 | ) | (1,246 | ) | |||
| Accounts payable and accrued expenses | 7,810 | 1,489 | |||||
| Provider liability | 85,174 | 123,930 | |||||
| Operating lease liabilities | (2,112 | ) | (2,510 | ) | |||
| Other long-term liabilities | — | (32 | ) | ||||
| Net cash provided by operating activities | 34,484 | 16,684 | |||||
| Cash from investing activities | |||||||
| Business acquisitions, net of cash acquired | (707 | ) | (37,858 | ) | |||
| Other | (5,006 | ) | (90 | ) | |||
| Net cash used in investing activities | (5,713 | ) | (37,948 | ) | |||
| Cash flows from financing activities | |||||||
| Proceeds from exercised stock options | 2,062 | 8,788 | |||||
| Repurchase of non-controlling interest | — | (5,694 | ) | ||||
| Contributed from non-controlling interest | 1,653 | 569 | |||||
| Net cash provided by financing activities | 3,715 | 3,663 | |||||
| Net increase (decrease) in cash and cash equivalents | 32,486 | (17,601 | ) | ||||
| Cash and cash equivalents at beginning of period | 389,511 | 347,992 | |||||
| Cash and cash equivalents at end of period | $ | 421,997 | $ | 330,391 | |||
| Supplemental disclosure of cash flow information: | |||||||
| Interest paid | $ | 222 | $ | 40 | |||
| Income taxes paid | $ | 3,525 | $ | 1,019 | |||
(i) Any slight variations in totals are due to rounding.
Additional Financial Information
Revenues disaggregated by source:
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||
| (Dollars in Thousands) | 2024 | 2023 | 2024 | 2023 | |||||||
| FFS-patient care | $ | 283,278 | $ | 245,569 | $ | 833,862 | $ | 704,346 | |||
| FFS-administrative services | 30,697 | 29,845 | 91,906 | 83,413 | |||||||
| Capitated revenue | 53,393 | 88,526 | 161,135 | 253,481 | |||||||
| Shared savings | 47,438 | 33,530 | 134,720 | 130,304 | |||||||
| Care management fees (PMPM) | 21,060 | 17,778 | 47,826 | 39,904 | |||||||
| Other revenue | 2,055 | 2,034 | 6,041 | 5,461 | |||||||
| Total Revenue | $ | 437,921 | $ | 417,282 | $ | 1,275,490 | $ | 1,216,909 | |||
The Company’s liabilities for unpaid medical claims under at-risk capitation arrangements:
| September 30, | ||||||||
| (Dollars in Thousands) | 2024 | 2023 | ||||||
| Balance, beginning of period | $ | 67,138 | $ | 28,617 | ||||
| Incurred health care costs: | ||||||||
| Current year | 156,899 | 246,004 | ||||||
| Prior years | 1,384 | 5,723 | ||||||
| Total claims incurred | $ | 158,283 | $ | 251,727 | ||||
| Claims paid: | ||||||||
| Current year | (97,883 | ) | (185,287 | ) | ||||
| Prior year | (52,461 | ) | (30,502 | ) | ||||
| Total claims paid | $ | (150,344 | ) | $ | (215,789 | ) | ||
| Balance, end of period | $ | 75,077 | $ | 64,555 | ||||
Key Metrics and Non-GAAP Financial Measures
Privia Health reviews a number of operating and financial metrics, including the following key metrics and non-GAAP financial measures, to evaluate the Company’s business, measure performance, identify trends affecting the Company’s business, formulate business plans, and make strategic decisions.
Key Metrics(j)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||
| (unaudited; $ in millions) | 2024 | 2023 | 2024 | 2023 | ||||||||
| Implemented Providers (as of end of period) (1) | 4,642 | 4,105 | 4,642 | 4,105 | ||||||||
| Attributed Lives (as of end of period) (2) | 1,247,000 | 1,094,000 | 1,247,000 | 1,094,000 | ||||||||
| Practice Collections (3) | $ | 739.9 | $ | 723.5 | $ | 2,175.6 | $ | 2,082.4 | ||||
| (1) Implemented Providers is defined as the total of all service professionals on Privia Health’s platform at the end of a given period who are credentialed by Privia Health and billed for medical services, in both Owned and Non-Owned Medical Groups during that period. | ||||||||||||
| (2) Attributed Lives are defined as any patient that a payer deems attributed to Privia to deliver care as part of a value-based care arrangement through a provider of primary care services as of the end of a particular period. | ||||||||||||
| (3) Practice Collections are defined as the total collections from all practices in all markets and all sources of reimbursement that the Company receives for delivering care and providing Privia Health’s platform and associated services. Practice Collections differ from revenue by including collections from Non-Owned Medical Groups. | ||||||||||||
| (j) Any slight variations in totals are due to rounding. | ||||||||||||
Non-GAAP Financial Measures (4)(k)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| (unaudited; $ in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Care Margin | $ | 101,420 | $ | 92,060 | $ | 296,117 | $ | 267,714 | ||||||||
| Platform Contribution | $ | 50,257 | $ | 45,181 | $ | 142,388 | $ | 131,199 | ||||||||
| Platform Contribution Margin | 49.6 | % | 49.1 | % | 48.1 | % | 49.0 | % | ||||||||
| Adjusted EBITDA | $ | 23,624 | $ | 18,774 | $ | 65,568 | $ | 54,950 | ||||||||
| Adjusted EBITDA Margin | 23.3 | % | 20.4 | % | 22.1 | % | 20.5 | % | ||||||||
(4) In addition to results reported in accordance with GAAP, Privia Health discloses Care Margin, Platform Contribution, Platform Contribution margin, Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. Each are defined as follows:
| ||||||||||||||||
| (k) Any slight variations in totals are due to rounding. | ||||||||||||||||
Reconciliation of Gross Profit to Care Margin(l)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| (unaudited; $ in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | $ | 437,921 | $ | 417,282 | $ | 1,275,490 | $ | 1,216,909 | ||||||||
| Provider expense | (336,501 | ) | (325,222 | ) | (979,373 | ) | (949,195 | ) | ||||||||
| Amortization of intangible assets | (1,506 | ) | (1,434 | ) | (4,560 | ) | (3,883 | ) | ||||||||
| Gross Profit | $ | 99,914 | $ | 90,626 | $ | 291,557 | $ | 263,831 | ||||||||
| Amortization of intangible assets | 1,506 | 1,434 | 4,560 | 3,883 | ||||||||||||
| Care margin | $ | 101,420 | $ | 92,060 | $ | 296,117 | $ | 267,714 | ||||||||
| (l) Any slight variations in totals are due to rounding. | ||||||||||||||||
Reconciliation of Gross Profit to Platform Contribution(m)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| (unaudited; $ in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | $ | 437,921 | $ | 417,282 | $ | 1,275,490 | $ | 1,216,909 | ||||||||
| Provider expense | (336,501 | ) | (325,222 | ) | (979,373 | ) | (949,195 | ) | ||||||||
| Amortization of intangible assets | (1,506 | ) | (1,434 | ) | (4,560 | ) | (3,883 | ) | ||||||||
| Gross Profit | $ | 99,914 | $ | 90,626 | $ | 291,557 | $ | 263,831 | ||||||||
| Amortization of intangible assets | 1,506 | 1,434 | 4,560 | 3,883 | ||||||||||||
| Cost of platform | (56,068 | ) | (50,324 | ) | (167,231 | ) | (145,254 | ) | ||||||||
| Stock-based compensation(5) | 4,905 | 3,445 | 13,502 | 8,739 | ||||||||||||
| Platform Contribution | $ | 50,257 | $ | 45,181 | $ | 142,388 | $ | 131,199 | ||||||||
| (m) Any slight variations in totals are due to rounding. | ||||||||||||||||
| (5) Amount represents stock-based compensation expense included in Cost of Platform. | ||||||||||||||||
Reconciliation of Net Income to Adjusted EBITDA(n)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| (unaudited; $ in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net income | $ | 3,535 | $ | 5,643 | $ | 9,986 | $ | 20,241 | ||||||||
| Net income (loss) attributable to non-controlling interests | 443 | 299 | 1,691 | (1,537 | ) | |||||||||||
| Provision for income taxes | 3,999 | 2,488 | 8,171 | 6,049 | ||||||||||||
| Interest income, net | (2,164 | ) | (2,894 | ) | (8,114 | ) | (5,524 | ) | ||||||||
| Depreciation and amortization | 1,797 | 1,731 | 5,436 | 4,761 | ||||||||||||
| Stock-based compensation | 15,106 | 10,801 | 41,401 | 25,429 | ||||||||||||
| Other expenses(6) | 908 | 706 | 6,997 | 5,531 | ||||||||||||
| Adjusted EBITDA | $ | 23,624 | $ | 18,774 | $ | 65,568 | $ | 54,950 | ||||||||
| (n) Any slight variations in totals are due to rounding. | ||||||||||||||||
| (6) Other expenses include employer taxes on equity vesting/exercises, severance and certain non-recurring costs. | ||||||||||||||||
Reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share(o)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||
| (unaudited; $ in thousands) | 2024 | 2023 | 2024 | 2023 | |||||||
| Net income | $ | 3,535 | $ | 5,643 | $ | 9,986 | $ | 20,241 | |||
| Stock-based compensation | 15,106 | 10,801 | 41,401 | 25,429 | |||||||
| Intangible amortization expense | 1,506 | 1,434 | 4,560 | 3,883 | |||||||
| Provision for income taxes | 3,999 | 2,488 | 8,171 | 6,049 | |||||||
| Other expenses(7) | 908 | 706 | 6,997 | 5,531 | |||||||
| Adjusted net income | $ | 25,054 | $ | 21,072 | $ | 71,115 | $ | 61,133 | |||
| Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic | $ | 0.21 | $ | 0.18 | $ | 0.60 | $ | 0.53 | |||
| Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted | $ | 0.20 | $ | 0.17 | $ | 0.57 | $ | 0.49 | |||
| Weighted average common shares outstanding – basic | 119,658,574 | 117,602,059 | 119,156,368 | 116,266,938 | |||||||
| Weighted average common shares outstanding – diluted | 125,751,006 | 124,924,442 | 125,457,540 | 124,646,849 | |||||||
| (o) Any slight variations in totals due to rounding. | |||||||||||
| (7) Other expenses include employer taxes on equity vesting/exercises, severance and certain non-recurring costs. | |||||||||||
| Last Trade: | US$19.47 |
| Daily Change: | -0.38 -1.91 |
| Daily Volume: | 295,028 |
| Market Cap: | US$2.340B |
October 29, 2024 August 08, 2024 January 29, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
